Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
about
Optimal combination of antiangiogenic therapy for hepatocellular carcinomaShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Thymostimulin in advanced hepatocellular carcinoma: a phase II trialTargeting Akt3 signaling in malignant melanoma using isoselenocyanates.Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients.Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II geneHepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.Embolotherapy in the management of hepatocellular carcinoma.Biomarkers for anti-angiogenic therapy in cancer.Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review)Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis.Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK SignalingTranslating the metastasis paradigm from scientific theory to clinical oncology.Evolving therapies in the treatment of hepatocellular carcinomaDownregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease.Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.Early development of sunitinib in hepatocellular carcinoma.Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft modelTargeted therapy in biliary tract cancer: 2009 update.Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibThe molecular pathogenesis and clinical implications of hepatocellular carcinoma.Prevention of recurrence after curative treatment for hepatocellular carcinoma.Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.Polyelectrolyte capsules as carriers for growth factor inhibitor delivery to hepatocellular carcinoma.Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells.Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?
P2860
Q26799458-FFB5DA36-4402-4E03-9987-4B841C649B01Q30240170-9B022A66-1E5C-4587-AF6B-925600731DFFQ33325625-C793667B-D42D-487C-92E7-37506635241EQ33408109-B49E4ABC-E1B2-45A6-9A87-59178E1C788FQ33767713-A577DD9A-82BD-43EF-A1F5-D8A2D745441BQ33770326-51BE7FE8-BDED-46D8-A45C-B76F5A867341Q33798661-A96160DA-27C9-458E-B430-4F00C33B840AQ33968053-7AE478A1-90AD-4D78-B972-E22F1939E0C7Q34045477-4F9A3E3C-3D87-4B77-913E-E4FFF8867C9AQ34131801-00B738CD-DE07-41CC-9290-87C9D65736E0Q34250146-81FEE07F-4CA2-4E01-926E-7675B3C3841CQ34404821-322089EC-C72F-4E9D-9EB0-1895BD7BE68FQ34409128-EAB7BB59-24E3-4096-BEC5-3A7865DD38ECQ34563655-94E7DF33-CD04-46BB-ACD8-2B2E1D044992Q34695003-BC80F491-C887-4925-928B-98A8E7F11306Q34993924-3548DF5B-1A3E-4135-86BF-B4E5C0362F07Q35180039-D91E5333-8831-4FF0-8BE1-66CC6AD5C5F1Q36160273-FA048933-746E-4787-8A7C-503F23D73A38Q36271326-880E8B1A-47A9-4707-B3FD-37A4AA3BBD05Q37195409-7CAF7F0A-84B3-4D11-B6B1-848FF941B0F9Q37290714-2C5372AF-AB19-47F9-BD8B-EC9C4A2B2CD3Q37301893-90E4079A-F6D4-4D81-B5E7-C7CEED4AF710Q37316980-DADD3218-92DD-4B4D-A7AF-8EFE35C01F0EQ37328115-EAAE1A94-4BE5-4F04-8B8A-080411AC729DQ37357314-72A873FB-FE16-4C95-8090-B8B5DBCCBBFEQ37578218-6C91EF64-4CC8-4CD4-BF65-CFBFBF686601Q37640370-D685DB8D-CCE3-41A0-89B9-17A30D431E5AQ37650623-2DAD2721-656B-45EA-9DD0-99FE086EB1A7Q37821302-7526234D-F695-4A6D-A5F0-522A6374BD81Q37970351-6B483AEC-D527-4F4B-87C8-3B8940A71D46Q38070128-B04040AD-17E0-4F37-BEFF-294623612DB5Q38993878-905ADAA4-4AB9-42B4-A0F9-DBEAB6AB874AQ39173251-596E4999-1A8E-4B67-AF0F-317A5CC8706EQ39384913-5D881C58-7884-4F88-A293-FEDFA727943CQ39929763-C69554D4-6F4F-46F7-BBCB-1CE0E745E5C6Q40001089-ED19AC10-B90A-4D50-ACFB-001417768E84Q42343451-8F415C16-E616-4E20-BAD8-DF7DA5A3ED76Q42635172-6E4A3844-DF90-447A-9C23-F26474DE25CCQ43607983-6EC44E5A-A50F-4492-8CD4-568BCD190D7DQ46179805-71FBEA85-CBA7-44C0-8D97-313E0CD7AED4
P2860
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@en
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@nl
type
label
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@en
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@nl
prefLabel
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@en
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@nl
P356
P1433
P1476
Development of sorafenib and o ...... s in hepatocellular carcinoma.
@en
P2093
Andrew X Zhu
P2860
P304
P356
10.1002/CNCR.23175
P407
P577
2008-01-01T00:00:00Z